Nexalin Device Improves Sleep Quality in Mild Alzheimer’s Patients in Sham-Controlled Study

• Nexalin Technology announced published TRANSFORM-AD results in the Journal of Alzheimer's Disease showing its brain-stimulation device significantly improved sleep in mild Alzheimer's patients.
• The randomized, blinded trial compared the Gen-2 SYNC device with sham treatment; neither group experienced serious adverse events.
• Benefits for anxiety, depression and quality of life remained inconclusive; the duration of sleep improvement is unknown.
• The publication is the fourth peer-reviewed article on the company's technology in Alzheimer's disease, including multiple analyses of TRANSFORM-AD.
• A U.S. pilot study is planned following FDA feedback on the device's potential De Novo classification pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270900PRIMZONEFULLFEED9853929) on October 27, 2026, and is solely responsible for the information contained therein.